Abatacept

Abatacept (marketed as Orencia) is a fusion protein composed of the Fc region of the immunoglobulin IgG1, fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα the... More
top ↑

Facts from the Community

From the BioVenturist base

Target/Biomolecule of Interest:

Developed by:

Brand Names:

  • Orencia

Stage of development:

top ↑

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!